US FDA approves Daiichi Sankyo's Tribenzor
This article was originally published in Scrip
Executive Summary
The US FDA has approved Daiichi Sankyo's Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics. The combination pill, which was formerly known as CS-8635, combines agents from each of these three classes.